Gain Therapeutics, Inc. (GANX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 48.66M |
| Enterprise value | 32.89M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 707.40 |
| Price/book (mrq) | 3.87 |
| Enterprise value/revenue | 596.08 |
| Enterprise value/EBITDA | -1.48 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.43 |
| 52-week change 3 | -42.69% |
| S&P500 52-week change 3 | 24.19% |
| 52-week high 3 | 5.6500 |
| 52-week low 3 | 2.0000 |
| 50-day moving average 3 | 3.9558 |
| 200-day moving average 3 | 3.5022 |
Share statistics
| Avg vol (3-month) 3 | 160.41k |
| Avg vol (10-day) 3 | 96.87k |
| Shares outstanding 5 | 16.22M |
| Implied shares outstanding 6 | 16.38M |
| Float 8 | 14.46M |
| % held by insiders 1 | 14.78% |
| % held by institutions 1 | 10.69% |
| Shares short (15 Apr 2024) 4 | 149.6k |
| Short ratio (15 Apr 2024) 4 | 1.28 |
| Short % of float (15 Apr 2024) 4 | 0.99% |
| Short % of shares outstanding (15 Apr 2024) 4 | 0.92% |
| Shares short (prior month 15 Mar 2024) 4 | 156.67k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -40,336.86% |
Management effectiveness
| Return on assets (ttm) | -65.14% |
| Return on equity (ttm) | -141.57% |
Income statement
| Revenue (ttm) | 55.18k |
| Revenue per share (ttm) | 0.00 |
| Quarterly revenue growth (yoy) | -100.00% |
| Gross profit (ttm) | N/A |
| EBITDA | -22.22M |
| Net income avi to common (ttm) | -22.27M |
| Diluted EPS (ttm) | -1.7100 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 16.79M |
| Total cash per share (mrq) | 1.03 |
| Total debt (mrq) | 1.03M |
| Total debt/equity (mrq) | 8.17% |
| Current ratio (mrq) | 3.59 |
| Book value per share (mrq) | 0.78 |
Cash flow statement
| Operating cash flow (ttm) | -18.87M |
| Levered free cash flow (ttm) | -9.8M |
© 2024 Yahoo. All rights reserved.